Key Findings
The North America Intrauterine contraceptive device market was estimated to be at $XX million in 2018. The market is predicted to rise over the forecast period of 2019-2027 at a CAGR of 3.55%, generating $XX million by the end of 2027.

North America intrauterine contraceptive devices market mainly covers the economic contribution of countries like the United States and Canada. North America intrauterine contraceptive market is driven by the increasing number of unplanned devices coupled with measures to control populations is boosting the intrauterine contraceptive devices market in the North America region during the forecast period of 2019-2027.

Market Insights
The market is being presented with opportunities like a high rate of unintended pregnancies, teen pregnancies, abortions, etc. across the region. The fact that these devices have a very low failure rate or side effects as compared to other contraceptive methods are increasing their popularity in the region. However, factors like limited access to contraceptives for the youths or the poor sections of the society coupled with the possible risks or infertility issues associated with these devices might restrain the market advancement in the future.

Competitive Insights
Egemen International, Meril Life Sciences Pvt. Ltd., Pfizer, Trimedic Supply Network Ltd., OCON Medical Ltd., Teva Pharmaceutical Industries Limited, HLL LifeCare Ltd., Bayers AG, Krishco Medical Products Pvt. Ltd., Pregna, Zhejiang Daji Medical Instruments Co., Ltd., Merck & Co., Melbea, SMB Corporation, Okamoto Industries Inc., Allergan PLC, Medisafe Distribution Inc., Mona Lisa N.V., DKT International, and Medicines360 are some of the prominent players in the market which have been profiled in detail within the report.